Grufity logoGrufity logo

TGTX

8.02USD-0.80(-9.07%)Market Closed

TG Therapeutics Inc

Market Summary

USD8.02-0.80Market Closed
-9.07%

TGTX Stock Price

RSI Chart

Valuation

Market Cap

831.0M

Price/Earnings

-2.88

Price/Sales

119.37

Price/Cashflow

-3.06

MarketCap/EBT

-2.09

Price/Sales

Profitability

EBT Margin

-5000.73%

Return on Equity

-223.58%

Return on Assets

-114.64%

Fundamentals

Revenue

Revenue Y/Y

-61.55%

Revenue Q/Q

-70.54%

Earnings

Earnings (TTM)

-288.5M

Earnings Y/Y

48.39%

Earnings Q/Q

41.3%

Price Action

52 Week Range

3.4820.69
(Low)(High)

Last 7 days

-1.8%

Last 30 days

27.7%

Last 90 days

17.9%

Trailing 12 Months

-48.9%

Financial Health

Current Ratio

4.68

Debt/Equity

0.53

Debt/Cashflow

-3.94

Investor Care

Shares Dilution (1Y)

1.68%

Diluted EPS (TTM)

-1.77

Peers (Alternatives to TG Therapeutics)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
10.02% 44.88%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
14.84% -44.72%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.18% 20.72%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
2.09% 56.47%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
3.35% 22.41%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
20.68% 45.72%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
7.80% 49.63%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-4.95% 10.70%
-18.85
63.29
26.15% -23.38%
3.8B
-
35.58% -30.70%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-1.55% -50.55%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-9.83% -50.35%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
18.96% 142.42%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-1.08% -8.90%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
33.59% -58.34%
-1.4
4.57
-43.57% -69.06%
16.0M
-
13.76% -81.10%
-0.46
19.11
-77.61% 5.14%

Financials for TG Therapeutics

Income Statement (Last 12 Months)
(In Thousands)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue-100.0%null6,9617,9126,6894,406
Operating Expenses-17.9%238,748290,849330,350351,459343,009
  S&GA Expenses-20.5%79,913100,558121,937128,090139,537
  R&D Expenses-16.4%158,363189,529207,526222,579202,893
Earnings Before Taxes--348,101.00
Net Income11.6%-288,498.00-326,485.00-348,101.00-342,980.00
* denotes actual numbers (not divided by Thousands)
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-13.4%218252303380410
  Current Assets-9.7%183203242331372
    Cash Equivalents-25.3%110147186299327
  Net PPE-15.9%00111
  Goodwill0%11111
Liabilities-4.3%11712313314298
  Current Liabilities-15.9%3643556588
  Long Term Debt1.6%7069676831
    LT Debt, Current-93.9%116---
    LT Debt, Non Current1.6%70696767-
Shareholder's Equity-22.1%100129170237312
  Retained Earnings-4.3%-1,500.00-1,438.22-1,397.71-1,328.70-1,200.00
  Additional Paid-In Capital0.5%1,5751,5671,5681,5661,547
Shares Outstanding0.1%145145145143143
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations12.0%-239.21-271.92-282.97-295.63-260.75
  Share Based Compensation-23.7%2229476180
Cashflow From Investing-7.7%-32.99-30.63-43.49-0.33-55.70
Cashflow From Financing15.9%56484141389

Risks

What is the probability of a big loss on TGTX?

100%


Probability that TG Therapeutics stock will be more than 20% underwater in next one year

96.2%


Probability that TG Therapeutics stock will be more than 30% underwater in next one year.

74.2%


Probability that TG Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does TGTX drawdown profile look like?

Y-axis is the maximum loss one would have experienced if TG Therapeutics was unfortunately bought at previous high price.

Returns

Cumulative Returns on TGTX

14.3%


10-Year Cumulative Returns

-7.0%


7-Year Cumulative Returns

-0.7%


5-Year Cumulative Returns

0.8%


3-Year Cumulative Returns

What are the long-term rolling returns for TGTX?

FIve years rolling returns for TG Therapeutics.

Which funds bought or sold TGTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-29
Bridgefront Capital, LLC
NEW
-
117,000
117,000
0.12%
2022-11-21
Parallax Volatility Advisers, L.P.
SOLD OFF
-100
-18,000
-
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
277,000
1,010,000
-%
2022-11-18
Spotlight Asset Group, Inc.
NEW
-
391,000
391,000
0.39%
2022-11-16
LIBERTY ONE INVESTMENT MANAGEMENT, LLC
REDUCED
-97.37
-182,000
1,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
ADDED
8,528.3
134,000
135,000
-%
2022-11-15
JACOBS LEVY EQUITY MANAGEMENT, INC
NEW
-
666,000
666,000
-%
2022-11-15
PUBLIC EMPLOYEES RETIREMENT ASSOCIATION OF COLORADO
UNCHANGED
-
29,000
102,000
-%
2022-11-15
CreativeOne Wealth, LLC
REDUCED
-4.9
15,000
61,000
-%
2022-11-15
ALLIANCEBERNSTEIN L.P.
UNCHANGED
-
262,000
929,000
-%

1–10 of 40

Latest Funds Activity

Are funds buying TGTX calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own TGTX

TG Therapeutics News

Invest Chronicle

TG Therapeutics Inc. (TGTX): This Stock is set to Soar Above its Peers.11 hours ago

Zacks Investment Research

New Haven Register

TGTX Fair Value

Recent SEC filings of TG Therapeutics

View All Filings
Date Filed Form Type Document
Nov 10, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Oct 11, 2022
SC 13G/A
Major Ownership Report
Sep 02, 2022
S-3ASR
S-3ASR

Latest Insider Trading transactions for TGTX

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-07-20
Charney Laurence N
ACQUIRED
-
-
43,732
-
2022-07-20
HUME DANIEL
ACQUIRED
-
-
43,732
-
2022-07-20
Hoberman Kenneth
ACQUIRED
-
-
43,732
-
2022-07-20
Echelard Yann
ACQUIRED
-
-
43,732
-
2022-07-20
Lonial Sagar
ACQUIRED
-
-
43,732
-
2022-07-20
Power Sean A
ACQUIRED
-
-
75,000
Chief Financial Officer
2022-01-05
Power Sean A
SOLD
-176,746
18.31
-9,653
CFO, Secretary and Treasurer
2022-01-05
WEISS MICHAEL S
SOLD
-561,586
18.31
-30,671
CEO and President
2022-01-04
WEISS MICHAEL S
SOLD
-720,941
19.2
-37,549
CEO and President
2022-01-04
Power Sean A
SOLD
-1,445,990
19.2
-75,312
CFO, Secretary and Treasurer

1–10 of 49

Michael S. Weiss
290
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

TGTX Income Statement

2022-09-30
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenue:    
Total revenue$ 94$ 2,030$ 2,705$ 4,368
Costs and expenses:    
Cost of product revenue2292262580
Research and development:    
Noncash compensation3,2494,5347,47119,061
Other research and development17,55247,43388,246140,872
Total research and development20,80151,96795,717159,933
Selling, general and administrative:    
Noncash compensation3,7409,46366327,857
Other selling, general and administrative10,51425,43646,84067,821
Total selling, general and administrative14,25434,89947,50395,678
Total costs and expenses35,05787,158143,482256,191
Operating loss(34,963)(85,128)(140,777)(251,823)
Other expense (income):    
Interest expense1,6481,0387,3294,559
Other income(793)(529)(2,765)(1,619)
Total other expense (income), net8555094,5642,940
Net loss$ (35,818)$ (85,637)$ (145,341)$ (254,763)
Basic net loss per common share (in dollars per share)$ (0.26)$ (0.65)$ (1.08)$ (1.93)
Diluted net loss per common share (in dollars per share)$ (0.26)$ (0.65)$ (1.08)$ (1.93)
Weighted-average shares used in computing basic net loss per common share (in shares)135,327,035132,353,119134,839,207132,109,912
Weighted-average shares used in computing diluted net loss per common share (in shares)135,327,035132,353,119134,839,207132,109,912
Product revenue, net [Member]    
Revenue:    
Total revenue$ 56$ 1,992$ 2,591$ 4,254
License revenue [Member]    
Revenue:    
Total revenue$ 38$ 38$ 114$ 114

TGTX Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 109,860$ 298,887
Short-term investment securities66,08215,876
Accounts receivable, net 1,389
Prepaid research and development4,02611,929
Other current assets2,9542,884
Total current assets182,922330,965
Restricted cash1,2691,264
Long-term investment securities21,76635,533
Right of use assets9,0798,629
Leasehold interest, net1,6801,839
Equipment, net376600
Goodwill799799
Total assets217,891379,629
Current liabilities:  
Accounts payable and accrued expenses29,72651,294
Other current liabilities8071,512
Loan payable - current portion 975
Lease liability - current portion1,6161,437
Accrued compensation4,29810,166
Total current liabilities36,44765,384
Deferred revenue, net of current portion343457
Loan payable - non-current70,03866,788
Lease liability - non-current10,5829,847
Total liabilities117,410142,476
Commitments and contingencies
Stockholders' equity:  
Common stock, $0.001 par value per share (175,000,000 shares authorized, 145,399,144 and 143,292,043 shares issued, 145,357,835 and 143,250,734 shares outstanding at September 30, 2022 and December 31, 2021, respectively)145143
Additional paid-in capital1,574,6091,565,942
Treasury stock, at cost, 41,309 shares at September 30, 2022 and December 31, 2021(234)(234)
Accumulated deficit(1,474,039)(1,328,698)
Total stockholders' equity100,481237,153
Total liabilities and stockholders' equity$ 217,891$ 379,629